41088-85-1

Basic information

• Product Name: carbobenzoxyhomoserine
• Synonyms: carbobenzoxyhomoserine;Cbz-D-Homoserine;N-[(Phenylmethoxy)carbonyl]-D-homoserine;N-[(Benzyloxy)carbonyl]hoMoserine;Cbz-D-HoMoser Cbz-D-HoMoserine Cbz-D-Hse;(R)-2-(((benzyloxy)carbonyl)amino)-4-hydroxybutanoic acid;N-Carbobenzoxy-D-homoserine
• CAS NO: 41088-85-1
• Molecular Formula: C₁₂H₁₅NO₅
• Molecular Weight: 253.2548
• Mol File: 41088-85-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 519.9 °C at 760 mmHg
• Flash Point: 268.2 °C
• Appearance: /
• Density: 1.311
• Vapor Pressure: 1.23E-11mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: carbobenzoxyhomoserine(CAS DataBase Reference)
• NIST Chemistry Reference: carbobenzoxyhomoserine(41088-85-1)
• EPA Substance Registry System: carbobenzoxyhomoserine(41088-85-1)

Safety Data

• Hazardous Substances Data: 41088-85-1(Hazardous Substances Data)

Usage

General Description

Carbobenzoxyhomoserine is a chemical compound that is part of the class of benzoic acid compounds. It is a modified form of the amino acid homoserine, containing a carbobenzoxy (Cbz) protective group on its amine functional group. carbobenzoxyhomoserine has been used in the synthesis of various peptide and protein derivatives, where the carbobenzoxy group can be selectively removed during the synthesis process to reveal the free amine group. Its chemical properties make carbobenzoxyhomoserine useful in the field of biochemistry and pharmaceutical research for the modification and synthesis of peptides and proteins.

InChI:InChI=1/C12H15NO5/c14-7-6-10(11(15)16)13-12(17)18-8-9-4-2-1-3-5-9/h1-5,10,14H,6-8H2,(H,13,17)(H,15,16)

Upstream product

• 6027-21-0 D-homoserine 
• 501-53-1 benzyl chloroformate 
• 3588-56-5 N-[(phenylmethoxy)carbonyl]-D-aspartic acid,1,1-dimethylethyl ester 
• 541-41-3 chloroformic acid ethyl ester 
• 498-19-1 L-(-)-homoserine 

Downstream Products

• 1159502-39-2 (R)-2-benzyloxycarbonylamino-4-hydroxybutyric acid, dicyclohexylamine salt 
• 1159502-43-8 4-[(R)-2-benzyloxycarbonylamino-4-(diethoxy-phosphoryl)-butyryl]-piperazine-1-carboxylic acid ethyl ester 
• 1159502-40-5 (R)-2-benzyloxycarbonylamino-4-(diethoxy-phosphoryl)-butyric acid methyl ester 
• 1159502-41-6 (R)-2-benzyloxycarbonylamino-4-(diethoxy-phosphoryl)-butyric acid 
• 82179-05-3 (R)-2-benzyloxycarbonylamino-4-bromo-butyric acid methyl ester 
• 369611-56-3 (R)-methyl 2-(((benzyloxy)carbonyl)amino)-4-hydroxybutanoate 
• 116536-02-8 n=5 
• 116506-92-4 n=4 
• 116506-91-3 n=3 
• 116506-90-2 n=2 
• 116506-89-9 n=1 
• 116506-88-8 (S)-2-Benzyloxycarbonylamino-4-[(2R,3R,4R,5S)-5-((R)-1,2-dihydroxy-ethyl)-3,4-dihydroxy-tetrahydro-furan-2-yloxy]-butyric acid 
• 116506-83-3 Caesium; 2-benzyloxycarbonylamino-4-trityloxy-butyrate 

Relevant articles and documents

EP300/CREBBP INHIBITOR

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula (I) wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

β-Lactones as a new class of cysteine proteinase inhibitors: inhibition of hepatitis A virus 3C proteinase by N-Cbz-serine β-Lactone

Formula presented N-Benzyloxycarbonyl-L-serine β-lactone (1) is shown to irreversibly inactivate the 3C cysteine proteinase of hepatitis A virus (HAV) with kinact = 0.70 min-1, KI = 1.84 x 10-4 M and kinact/KI = 3800 M-1 min-1 at an enzyme concentration of 0.1 μM. Mass spectrometric and HMQC NMR studies using 13C-labeled 1 show that the active site cysteine (Cys-172) thiol of the HAV 3C proteinase attacks the β-position (i.e. C-4) of the oxetanone ring, thereby leading to ring opening and alkylation of the sulfur. In contrast, the enantiomer of this β-lactone, 2, is a reversible competitive inhibitor (Ki = 1.50 x 10-6 M) at similar enzyme concentrations. The β-lactone motif represents a new class of inhibitors of cysteine proteinases.